NCT02404675View on ClinicalTrials.gov

High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation

PHASE4UnknownINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

September 30, 2018

Conditions
NSCLC
Interventions
DRUG

icotinib

Trial Locations (1)

Unknown

RECRUITING

Beijing Chest Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY